LifeStance Health Group Inc. Common Stock Q2 2026 Earnings Recap

LifeStance Health’s Q2 results surpassed expectations, driving a 4.5% stock increase as revenue growth, clinician productivity, and margin expansion outpaced projections.

Key Takeaways

• Revenue grew 26% year-over-year to $435 million, led by 19% higher visit volumes and a 6% rise in revenue per visit.
• Clinician base increased 11% to 8,542, with visits per clinician up 7%, sustaining strong productivity gains.
• Adjusted EBITDA nearly doubled, rising 94% to $66 million, lifting EBITDA margin by over 500 basis points to 15.2%.
• Center Margin improved 41% to $153 million, reaching 35.2% of revenue, driven primarily by revenue strength.
• Free cash flow of $88 million reflects solid collections and favorable payroll timing, supporting a healthy balance sheet with $226 million in cash.